Abiopharma

News list

Gormley Glenn 🟢 acquired 37.9K shares (1 derivative) of Aktis Oncology, Inc. (AKTS) at $18.09 Transaction Date: Apr 15, 2026 | Filing ID: 159028

Full text

News bot April 16, 2026, 8:15 p.m.
🔍 Gormley Glenn (Executive)

Company: Aktis Oncology, Inc. (AKTS)

Report Date: 2026-04-15
Transaction Summary:
- Total transactions: 1
- Derivative instruments: 1
- Holdings reported: 0
- Total shares acquired: 37,866
Detailed Transactions and Holdings:
- Acquired 37,866 shares of Stock Option (Right to Buy) at $18.09 per share (Derivative)
  Date: 2026-04-15 | Code: A | Expires: 2036-04-15 | equity_swap_involved: false | shares_owned_after: 37,866.00 | transaction_form_type: 4 | Footnotes: F1
Footnotes:
- F1: 1/3 of the original number of shares subject to the option shall vest on April 15, 2027, and 1/3 of the original number of shares subject to the option shall vest in equal annual installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.